Zelio E-Mobility Ltd opened its Initial Public Offering (IPO) on September 30, 2025. The bidding window for the Zelio E-Mobility IPO was open till October 3, 2025 and the allotment process for the IPO is expected to be finalised today on October 6, 2025.
Zelio E-Mobility Ltd is an Indian EV manufacturer that produces electric two-wheelers and three-wheelers (e-rickshaws). The shares of the company will be listed on BSE and the tentative listing date is fixed as October 8, 2025.
Here is the process to check Zelio E-Mobility IPO Allotment on BSE:
[October 3, 2025, end of the day]
On day 3, Zelio E-Mobility IPO was subscribed 1.50 times. The public issue was subscribed 1.32 times in the individual investors category, 1.61 times in QIB, and 1.76 times in the NII category.
Zelio E-Mobility IPO was a book build issue of ₹78.34 crores. The issue was a combination of fresh issue of 0.46 crore shares aggregating to ₹62.83 crores and offer for sale of 0.11 crore shares aggregating to ₹15.50 crores. The IPO price band was set at ₹129 to ₹136 per share . The minimum lot size for an application was 1000. The minimum amount of investment required by an individual investor (retail) was ₹2,72,000 (2000 shares) based on upper price.
Hem Securities Ltd. was the book running lead manager and Maashitla Securities Pvt.Ltd. was the registrar of the issue. The market maker of the company was Hem Finlease Pvt.Ltd.
Zelio E-Mobility Ltd is an electric vehicle manufacturer focused on two-wheelers (‘Zelio’ brand) and three-wheelers (‘Tanga’ brand), based in Hisar, Haryana. Incorporated recently, it has built an installed capacity of ~72,000 EV units/year at its Hisar plant, with plans to expand in South & East India. It sells through over 280 dealers across more than 20 states/UTs.
In FY 2025, Zelio reported revenue of ₹172 crore, EBITDA of ₹21 crore, and a Profit After Tax (PAT) of ₹16 crore. Its net worth stood at ₹26.67 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.